Orchard

ANGRY ORCHARD IS HELPING SPRING BREAKERS TRAVEL LIGHT TO CELEBRATE THE LAUNCH OF NEW LIGHT HARD CIDER

Retrieved on: 
Thursday, February 29, 2024

Angry Orchard, the nation’s leading hard cider maker, is stepping in to help: the days of schlepping a week’s worth of drinks to vacation destinations are officially over.

Key Points: 
  • Angry Orchard, the nation’s leading hard cider maker, is stepping in to help: the days of schlepping a week’s worth of drinks to vacation destinations are officially over.
  • To celebrate the launch of its NEW Crisp Light, Angry Orchard is helping lucky spring breakers ”Travel Light” by eliminating the hassle of hauling alcohol in their luggage with a chance to win a fully stocked beverage fridge at their spring break destination, so they can drop their bags at the door and get the party started light…er, right.
  • Angry Orchard Crisp Light is the newest addition to the Crisp Apple lineup, making a big splash as the perfect day-drinking cider for its lighter taste and profile, now available in 12oz.
  • For more information on where to find Angry Orchard Crisp Light Cider, please visit AngryOrchard.com and follow along @AngryOrchard on Facebook, Twitter, and Instagram.

DENNY STRICKLAND DROPS 'DENNY MODE': AN EXPLOSIVE NEW ALBUM WITH CHART TOPPING HITS, AVAILABLE MARCH 1ST, 2024

Retrieved on: 
Friday, March 1, 2024

LOS ANGELES, March 1, 2024 /PRNewswire/ -- Denny Strickland is back in the spotlight with the release of his long-awaited album, "Denny Mode," marking a grand return to the music scene.

Key Points: 
  • LOS ANGELES, March 1, 2024 /PRNewswire/ -- Denny Strickland is back in the spotlight with the release of his long-awaited album, "Denny Mode," marking a grand return to the music scene.
  • This album not only showcases Strickland's signature fusion of genres but also introduces new collaborations with Project Pat on tracks like "Dime Piece" and the album's titular song, "Denny Mode."
  • Listening to "Denny Mode" is akin to embarking on a journey through the universe of its main character.
  • Stay connected with Denny Strickland's musical journey through his official website www.dennystrickland.com and follow his latest updates on social media channels.

Pinkfong's Baby Shark Bags its First Gold Certification in France

Retrieved on: 
Tuesday, February 6, 2024

SEOUL, South Korea, Feb. 6, 2024 /PRNewswire/ -- The Pinkfong Company, the global entertainment company behind Baby Shark, today announced that its Baby Shark single received its first official Gold certification from France's National Syndicate of Phonographic Publishing (SNEP). With 15 million cumulative streams in France, Pinkfong's "Baby Shark" made history as the first Korean animation to earn gold certification in France.

Key Points: 
  • With 15 million cumulative streams in France, Pinkfong's "Baby Shark" made history as the first Korean animation to earn gold certification in France.
  • Baby Shark has captured the hearts of listeners in Europe, earning additional certifications across Europe with its iconic song.
  • According to The Official Charts in December 2022, Pinkfong's Baby Shark placed 8th on the UK's Official Top 200 most-streamed song chart.
  • The world-renowned "Baby Shark" song became a breakout sensation, recording a 20-week streak on the Billboard Hot 100 and receiving RIAA Diamond certification (11x Platinum).

Orchard Therapeutics Announces First Patient Randomized in Registrational Trial of OTL-203 for MPS-I Hurler Syndrome

Retrieved on: 
Monday, February 5, 2024

TOKYO, LONDON and BOSTON, Feb. 05, 2024 (GLOBE NEWSWIRE) -- Orchard Therapeutics, recently acquired by Kyowa Kirin with the goal of accelerating the delivery of new gene therapies to patients around the globe, today announced the first patient has been randomized at the M Health Fairview Masonic Children’s Hospital in a registrational trial evaluating the efficacy and safety of OTL-203, an investigational hematopoietic stem cell (HSC) gene therapy, in patients with the Hurler subtype of mucopolysaccharidosis type I (MPS-IH). The trial, referred to as HURCULES, compares treatment with OTL-203 to standard of care with allogeneic hematopoietic stem cell transplant (HSCT), and is expected to enroll 40 MPS-IH patients at sites across the U.S. and Europe.

Key Points: 
  • Approximately 60 percent of children born with MPS-I have the most severe subtype, MPS-IH, also called Hurler syndrome, and rarely live past the age of 10 when untreated.
  • Current treatment options for MPS-IH include allogeneic hematopoietic stem cell transplant (HSCT) and enzyme replacement therapy (ERT), both of which have significant limitations.
  • One patient experienced an acute hypersensitivity reaction that was considered probably related to HSC gene therapy.
  • The viral vector integration profile was comparable with other Orchard Therapeutics lentiviral-based HSC gene therapy studies, and all participants had a stable and highly polyclonal repertoire.

Orchard Therapeutics Announces Agreement with the Beneluxa Consortium Enabling Reimbursed Access to Libmeldy

Retrieved on: 
Thursday, January 25, 2024

BOSTON and LONDON, Jan. 25, 2024 (GLOBE NEWSWIRE) -- Orchard Therapeutics, a global gene therapy leader, today announced the company has reached an agreement with the Beneluxa Initiative on Pharmaceutical Policy (Beneluxa) enabling reimbursed access to Libmeldy® (atidarsagene autotemcel), a hematopoietic stem cell (HSC) gene therapy, approved for the treatment of early-onset metachromatic leukodystrophy (MLD).

Key Points: 
  • BOSTON and LONDON, Jan. 25, 2024 (GLOBE NEWSWIRE) -- Orchard Therapeutics, a global gene therapy leader, today announced the company has reached an agreement with the Beneluxa Initiative on Pharmaceutical Policy (Beneluxa) enabling reimbursed access to Libmeldy® (atidarsagene autotemcel), a hematopoietic stem cell (HSC) gene therapy, approved for the treatment of early-onset metachromatic leukodystrophy (MLD).
  • With more than a cumulative 250 patient-years of follow-up, Libmeldy was generally well-tolerated, with no treatment-related serious adverse events or deaths.
  • “We are pleased to have reached an agreement with the Beneluxa consortium that enables sustainable access to treatment.
  • Multiple eligible MLD patients are currently in the treatment process and expected to receive Libmeldy in the coming months.

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates PFIN, FRLN, AMTI, ORTX

Retrieved on: 
Wednesday, November 29, 2023

If you are a P&F shareholder, click here to learn more about your rights and options .

Key Points: 
  • If you are a P&F shareholder, click here to learn more about your rights and options .
  • If you are a Freeline shareholder, click here to learn more about your rights and options .
  • Please call Daniel Sadeh or Zachary Halper at (212) 763-0060 or email [email protected] or [email protected] .
  • Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct.

Orchard Therapeutics Reports Third Quarter 2023 Financial Results and Highlights Recent Business Accomplishments

Retrieved on: 
Monday, November 13, 2023

Biologics License Application for OTL-200 in MLD accepted by U.S. FDA under Priority Review; PDUFA date set for March 18, 2024

Key Points: 
  • Biologics License Application for OTL-200 in MLD accepted by U.S. FDA under Priority Review; PDUFA date set for March 18, 2024
    BOSTON and LONDON, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced several business accomplishments along with its financial results for the quarter ended September 30, 2023.
  • Following the completion of the acquisition, Orchard Therapeutics will become a wholly-owned subsidiary of Kyowa Kirin.
  • The company had approximately 227.3 million ordinary shares, equivalent to 22.7 million American Depositary Shares, outstanding as of September 30, 2023.
  • As a result of the anticipated acquisition by Kyowa Kirin, Orchard Therapeutics has removed its financial guidance around Libmeldy revenue and anticipated cash runway.

KB Home Announces the Grand Opening of Its Newest Master-Planned Community, Parkwood, in Popular Hughson, California

Retrieved on: 
Friday, December 1, 2023

KB Home (NYSE: KBH) today announced the grand opening of its newest master-planned community, Parkwood, in desirable Hughson, California.

Key Points: 
  • KB Home (NYSE: KBH) today announced the grand opening of its newest master-planned community, Parkwood, in desirable Hughson, California.
  • View the full release here: https://www.businesswire.com/news/home/20231201993748/en/
    KB Home announces the grand opening of its newest master-planned community, Parkwood, in popular Hughson, California.
  • Every KB home is uniquely built for each customer, so no two KB homes are the same.
  • KB homes are engineered to be highly energy and water efficient and include features that support healthier indoor environments.

Veritone Announces Licensing Deal with Orchard Clips to Increase Accessibility of International Content

Retrieved on: 
Thursday, November 30, 2023

(NASDAQ: VERI), a leader in designing human-centered AI solutions, today announced a content licensing agreement with Orchard Clips, a division of UK-based OR Media Group and a preeminent source of Middle Eastern content.

Key Points: 
  • (NASDAQ: VERI), a leader in designing human-centered AI solutions, today announced a content licensing agreement with Orchard Clips, a division of UK-based OR Media Group and a preeminent source of Middle Eastern content.
  • Orchard Clips will leverage Veritone’s extensive network of buyers to enhance content licensing opportunities in the Americas and generate additional revenue.
  • View the full release here: https://www.businesswire.com/news/home/20231130428424/en/
    Veritone announces licensing deal with Orchard Clips to increase accessibility of international content.
  • “We are thrilled to expand our relationship with Orchard Clips, which further solidifies our commitment to delivering premium content to our customers,” said Jay Bailey, Vice President of Content Licensing and Operations at Veritone.

ORCHARD THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Orchard Therapeutics plc - ORTX

Retrieved on: 
Tuesday, November 28, 2023

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq.

Key Points: 
  • Former Attorney General of Louisiana Charles C. Foti, Jr., Esq.
  • and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Orchard Therapeutics plc (NasdaqCM: ORTX) to Kyowa Kirin Co., Ltd.
  • KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company.
  • To learn more about KSF, whose partners include the Former Louisiana Attorney General, visit www.ksfcounsel.com .